{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:03:56Z","timestamp":1746763436137,"version":"3.40.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10096-025-05038-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:18:51Z","timestamp":1740608331000},"page":"1265-1271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotyping and treatment issues with \u2018unusual\u2019 HCV 1 subtypes"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-4891","authenticated-orcid":false,"given":"Cinzia","family":"Caudai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Pierotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6281","authenticated-orcid":false,"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"5038_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","volume":"218","author":"SM Borgia","year":"2018","unstructured":"Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM et al (2018) Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 218:1722\u20131729. https:\/\/doi.org\/10.1093\/infdis\/jiy401","journal-title":"J Infect Dis"},{"key":"5038_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jhep.2019.09.021","volume":"71","author":"JM Pawlotsky","year":"2019","unstructured":"Pawlotsky JM (2019) DAA failures in African patients with \u2018\u201cunusual\u201d\u2019 HCV subtypes: hey! Didn\u2019t you know there was another world? J Hepatol 71:1070\u20131072. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.021","journal-title":"J Hepatol"},{"key":"5038_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2020.05.029","volume":"73","author":"D Nguyen","year":"2020","unstructured":"Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P et al (2020) Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Hepatology 73:794\u2013799. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.029","journal-title":"Hepatology"},{"key":"5038_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","volume":"71","author":"K Childs","year":"2019","unstructured":"Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L et al (2019) Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C. J Hepatol 71:1099\u20131105. https:\/\/doi.org\/10.1016\/j.jhep.2019.07.025","journal-title":"J Hepatol"},{"key":"5038_CR5","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1093\/nar\/gku739","volume":"42","author":"D Struck","year":"2014","unstructured":"Struck D, Lawyer G, Ternes AM, Schmit JC, Perez Bercoff D (2014) COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res 42:e144. https:\/\/doi.org\/10.1093\/nar\/gku739","journal-title":"Nucleic Acids Res"},{"key":"5038_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","volume":"21","author":"C Kuiken","year":"2005","unstructured":"Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21:379\u2013384. https:\/\/doi.org\/10.1093\/bioinformatics\/bth485","journal-title":"Bioinformatics"},{"key":"5038_CR7","doi-asserted-by":"publisher","first-page":"e0155869","DOI":"10.1371\/journal.pone.01559869","volume":"11","author":"P Kalaghatgi","year":"2016","unstructured":"Kalaghatgi P, Sikorski AM, Knops E, Rupp D, Sierra S, Heger E et al (2016) Geno2pheno[HCV] \u2013 a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting-antiviral-agents. PLoS-One 11:e0155869. https:\/\/doi.org\/10.1371\/journal.pone.01559869","journal-title":"PLoS-One"},{"key":"5038_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","volume":"37","author":"MC Sorbo","year":"2018","unstructured":"Sorbo MC, Cento V, Di Maio V, Howe AY, Garcia F, Perno CF et al (2018) Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resistance Update 37:17\u201339. https:\/\/doi.org\/10.1016\/j.drup.2018.01.004","journal-title":"Drug Resistance Update"},{"key":"5038_CR9","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/hep.29693","volume":"67","author":"PR Harrington","year":"2018","unstructured":"Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O\u2019Rear JJ, Naeger LK et al (2018) Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology 67:2430\u20132448. https:\/\/doi.org\/10.1002\/hep.29693","journal-title":"Hepatology"},{"key":"5038_CR10","doi-asserted-by":"publisher","first-page":"e02558","DOI":"10.1128\/AAC.02558-16","volume":"61","author":"PT Krishnan","year":"2017","unstructured":"Krishnan PT, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T et al (2017) In vitro antiviral activity and resistance profile of the next-generation hepatitis c virus NS5A inhibitor Pibrentasvir. Antimicrob Agent Chemother 61:e02558-e2616. https:\/\/doi.org\/10.1128\/AAC.02558-16","journal-title":"Antimicrob Agent Chemother"},{"key":"5038_CR11","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1128\/AAC.00051-16","volume":"60","author":"FC Lahser","year":"2016","unstructured":"Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P et al (2016) The combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3\/4A protease Inhibitor, and Elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV Genotype 1a replicons. Antimicrob Agent Chemoter 60:2954\u20132964. https:\/\/doi.org\/10.1128\/AAC.00051-16","journal-title":"Antimicrob Agent Chemoter"},{"key":"5038_CR12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","volume":"154","author":"JM Gottwein","year":"2018","unstructured":"Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TK et al (2018) Efficacy of NS5A inhibitors against Hepatitis C Virus genotypes 1\u20137 and escape variants. Gastroenterology 154:1435\u20131448. https:\/\/doi.org\/10.1053\/j.gastro.2017.12.015","journal-title":"Gastroenterology"},{"key":"5038_CR13","doi-asserted-by":"publisher","unstructured":"(2020) EASL recommendations on treatment of HCV: final update of the series . J Hepatol 73:1170-1218. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.018","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"5038_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","volume":"157","author":"AS Lok","year":"2019","unstructured":"Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML et al (2019) Efficacy of Glecaprevir and Pibrentasvir in patients with genotype 1 Hepatitis C Virus infection with treatment failure after NS5A inhibitor plus Sofosbuvir therapy. Gastroenterology 157:1506-1517.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.008","journal-title":"Gastroenterology"},{"key":"5038_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","volume":"70","author":"D Wyles","year":"2019","unstructured":"Wyles D, Weiland O, Yao O, Dufour JF, Gordon SC, Stoehr A et al (2019) Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection. J Hepatol 70:1019\u20131038. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.031","journal-title":"J Hepatol"},{"issue":"607\u2013620","key":"5038_CR16","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1097\/HEP.0000000000000379","volume":"78","author":"E Vo-Quang","year":"2023","unstructured":"Vo-Quang E, Soulier A, Ndebi M, Rodriguez C, Chevaliez S, Leroy V et al (2023) Virological characterization of treatment failures and retreatment outcomes in patients infected with \u201cunusual\u201d-HCV-genotype-1-subtypes. Hepatology 78(607\u2013620):2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000379","journal-title":"Hepatology"},{"key":"5038_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","volume":"66","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R et al (2017) NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment out come. J Hepatol 66:910\u2013918. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.007","journal-title":"J Hepatol"},{"key":"5038_CR18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/jiab110","volume":"226","author":"E Aranday-Cortes","year":"2022","unstructured":"Aranday-Cortes E, Patrick McClure C, Davis C, Irving LW, Adeboyejo K, Tong L et al (2022) Real-world outcomes of direct-acting antiviral treatment and retreatment in United Kingdom-based patients infected with hepatitis C virus genotypes\/subtypes endemic in Africa. J Infect Dis 226:995\u20131004. https:\/\/doi.org\/10.1093\/infdis\/jiab110","journal-title":"J Infect Dis"},{"key":"5038_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","volume":"17","author":"AL Cox","year":"2020","unstructured":"Cox AL, El-Sayed MH, Kao JH, Lazarus JV, LemoineM LAS, Zoulim F (2020) Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol 17:533\u2013542. https:\/\/doi.org\/10.1038\/s41575-020-0332-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5038_CR20","doi-asserted-by":"publisher","first-page":"e0194396","DOI":"10.1371\/journal.pone.0194396","volume":"13","author":"B Nemoz","year":"2018","unstructured":"Nemoz B, Roger L, Leroy V, Poveda JD, Morand P, Larrat S (2018) Evaluation of the cobas\u00ae GT hepatitis C virus genotyping assay in G1\u20136 viruses including low viral loads and LiPA failures. PLoS ONE 13:e0194396. https:\/\/doi.org\/10.1371\/journal.pone.0194396","journal-title":"PLoS ONE"},{"key":"5038_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcv.2019.01.012","volume":"113","author":"A Walker","year":"2019","unstructured":"Walker A, Ennker KS, Kaiser R, L\u00fcbke N, Timm J (2019) A pan-genotypic Hepatitis C Virus NS5A amplification method for reliable genotyping and resistance testing. J Clin Virol 113:8\u201313. https:\/\/doi.org\/10.1016\/j.jcv.2019.01.012","journal-title":"J Clin Virol"},{"key":"5038_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1136\/gutjnl-2024-332177","volume":"73","author":"E Vo-Quang","year":"2024","unstructured":"Vo-Quang E, Pawlotsky J-M (2024) \u2018Unusual\u2019 HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and re treatment. Gut 73:1570\u20131582. https:\/\/doi.org\/10.1136\/gutjnl-2024-332177","journal-title":"Gut"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05038-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05038-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:54:36Z","timestamp":1746708876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05038-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5038"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05038-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that no financial support was\u00a0received in relation to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This retrospective study was performed to characterize the viral variants only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to partecipate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}